 |
|
| Save the date: Partnering for Cures is going on the road » |
Partnering for Cures connects hundreds of decision-makers from across the medical research system who are motivated by the same mission: to reduce the time and cost of getting new therapies from discovery to patients. We are excited to be in new cities this year and look forward to meeting new health innovators! Join us in Boston on July 12 or in San Francisco on Nov. 14.
|
|
 |
 Margaret Anderson says it’s time for a “health citizenship” movement in Science Translational Medicine »
In a recent issue of the journal Science Translational Medicine, FasterCures' executive director, Margaret Anderson, introduces the concept of health citizenship. Anderson explains that FasterCures sees health citizenship as a two-way street: Individual citizens have a responsibility to engage in their own heath and in the biomedical research system, and “the system” has a responsibility to facilitate and value participant engagement.
|
 Register now for free webinar on changing organizational culture in medical R&D »
What can the biomedical R&D ecosystem learn from the vast literature and learnings from outside the space about how to change organizational culture and behavior to build a more effective, efficient enterprise? Join us for the discussion Wednesday, March 29 at 2:00 p.m. ET.
|
 Pulse check on patient-centricity: 7 vital signs (as seen in the Timmerman Report) »
Kim McCleary takes a look at recent developments in patient-centricity. These reflections come five years after Leonard Kish, a health IT strategy consultant, predicted that patient-centricity would be "the blockbuster drug of the century." The list highlights: climbing the adoption curve, progress toward objective evaluation, alignment on value, federal policy and growing respect for patient data.
|
 The power of language: 4 steps to advance the conversation about patient engagement »
FasterCures expands on findings from the “Expanding the Science of Patient Input: The Power of Language” report with “Four Steps to Advance the Conversation about Patient Engagement.” If we want to build the science of patient input, our language needs to be clear and easy to understand.
|
 In case you missed it: Top Medical Research Issues and Trends to Watch in 2017 »
FasterCures kicked of 2017 by giving Webinar listeners a snapshot of the organization’s popular annual “Top Medical Research Issues and Trends to Watch in 2017” list and welcomed a trio of distinguished FasterCures senior fellows to offer their own expert insights. Access the session recording and summary on our website.
|
|
 |
T he Alpha-1 Foundation remembers John Walsh »
John Walsh, a dedicated patient advocate who co-founded and led the Alpha-1 Foundation and COPD Foundation, passed away this month. Walsh led the Alpha-1 Foundation for more than 20 years, and under his leadership the organization became internationally recognized for its commitment to people affected by Alpha–1 and driving for the cure by investing over $65 million in research and programs worldwide.
|
|
 MJFF with 23andMe announce Parkinson’s disease Research Collaboration Program »
23andMe and The Michael J. Fox Foundation (MJFF) seek proposals for collaborative Parkinson’s disease research using the 23andMe research database and its genotyped cohort. Researchers may propose analyses to conduct with 23andMe scientists. Sharing of complementary data resources and application of new methodologies are highly encouraged.
|
|
 Chordoma Foundation recommends new treatment pathway for patients »
The Chordoma Foundation Medical Advisory Board has recommended a new path for patients with advanced or recurrent chordoma to follow when seeking treatment, based on the availability of clinical trials testing new therapies. |
|
 Cure SMA-supported therapy approved by FDA »
The FDA announced that it has approved Spinraza (nusinersen) to treat spinal muscular atrophy (SMA), making it the first-ever FDA-approved therapy for SMA. Cure SMA’s efforts were vital to the approval of Spinraza by providing the first research funding needed to begin investigation into this therapeutic approach.
|
|
 Exonics Therapeutics launches with funding from CureDuchenne Ventures to advance therapy for Duchenne muscular dystrophy »
CureDuchenne Ventures, LLC, a subsidiary of the nonprofit CureDuchenne, has made a commitment of $5 million in initial seed funding that will allow Exonics Therapeutics to advance its preclinical research into developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases.
|
|
|
 |
|
|
About TRAIN
Disease research organizations focus on curing diseases, not fixing the research system. But they are all delayed, and occasionally defeated, by the same systemic, cultural obstacles that slow medical progress. At FasterCures, it is our mission to knock down these obstacles so researchers won't have to, so every patient can benefit. The Research Acceleration and Innovation Network (TRAIN) was established to create opportunities for medical research innovators to discuss and tackle the challenges that cut across diseases. |
|
|
|
|
FASTERCURES
Our name. Our mission.
Manage subscriptions | Opt-Out from all emails |
| © 2017 Milken Institute | 1101 New York Avenue, NW | Suite 620 | Washington, DC | +1 202 336 8900 |
|